Abstract:Introduction Progressive supranuclear palsy (PSP) is a four-repeat tauopathy characterized by multiple clinicopathologic subtypes. Advanced neuroimaging techniques have shown an early ability to distinguish PSP subtypes non-invasively for improved diagnosis. This study utilized tau-PET imaging and MRI techniques at 7 Tesla (7T) to determine the neuroimaging profile of a participant with comorbid PSP and amyotrophic lateral sclerosis (ALS). Method [18F]-flortaucipir PET imaging was performed on one participant with PSP-ALS, one participant with typical PSP (Richardson’s syndrome; PSP-RS), and 15 healthy control volunteers. Standardized uptake value ratio (SUVR) in each brain region was compared between PSP participants and controls. Quantitative susceptibility mapping (QSM) and inflow-based vascular-space occupancy (iVASO) MRI at 7T were performed on the two PSP participants and on two age-matched healthy controls to evaluate for differences in regional brain iron content and arteriolar cerebral blood volume (CBVa), respectively. Results In the participant with PSP-ALS, the precentral gyrus demonstrated the highest [18F]-flortaucipir uptake of all brain regions relative to controls (z-score 1.94). In the participant with PSP-RS, [18F]-flortaucipir uptake relative to controls was highest in subcortical regions, including the pallidum, thalamus, hippocampus, and brainstem (z-scores 1.08, 1.41, 1.49, 1.32, respectively). Susceptibility values as a measure of brain iron content were higher in the globus pallidus and substantia nigra than in the midbrain and pons in each participant, regardless of group. CBVa values tended to be higher in the subcortical gray matter in PSP participants than in controls, although large measurement variability was noted in controls across multiple regions. Conclusion In vivo tau PET imaging of an individual with PSP-ALS overlap demonstrated increased tau burden in the motor cortex that was not observed in PSP-RS or control participants. Consistent with prior PET studies, tau burden in PSP-RS was mainly observed in subcortical regions, including the brainstem and basal ganglia. QSM data suggest that off-target binding to iron may account for some but not all of the increased [18F]-flortaucipir uptake in the basal ganglia in PSP-RS. These findings support existing evidence that tau PET imaging can distinguish among PSP subtypes by detecting distinct regional patterns of tau deposition in the brain. Larger studies are needed to determine whether CBVa is sensitive to changes in brain microvasculature in PSP.

18F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype

In Vivo <scp><sup>18</sup>F‐Florzolotau</scp> Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

In Vivo F-18-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

Co-registration Analysis of Fluorodopa and Fluorodeoxyglucose Positron Emission Tomography for Differentiating Multiple System Atrophy Parkinsonism Type from Parkinson's Disease

<SUP>18</SUP>F-Florzolotau Positron Emission Tomography Imaging of Tau Pathology in the Living Brains of Patients with Corticobasal Syndrome

18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy

Subcortical tau burden correlates with regional brain atrophy and plasma markers in four-repeat tauopathy parkinsonism

In Vivo 18 F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia.

In Vivo Cerebral Metabolic and Dopaminergic Characteristics in Multiple System Atrophy with Orthostatic Hypotension.

Dopamine Transporter PET Imaging in Patients with Parkinson Variant of Multiple System Atrophy and Parkinson''s Disease

Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes

In Vivo18F‐APN‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

In Vivo 18 F‐APN ‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

Clinical Utility of 18 F‐APN ‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

Improved Interpretation of 18F-Florzolotau PET in Progressive Supranuclear Palsy Using a Normalization-Free Deep-Learning Classifier.

Visual Reading for [18f]florzolotau Tau PET Scans in Progressive Supranuclear Palsy

Cerebral tau deposition in co-morbid progressive supranuclear palsy and amyotrophic lateral sclerosis: an [18F]-flortaucipir and 7T MRI study

[The Clinical Application Value of Brain 18F-FDG PET/CT in the Diagnostics of Parkinsonian Syndromes].

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease